Placebo response is universally observed in randomized controlled trials (RCTs), yet these 34 effects are commonly dismissed as consequences of uncontrollable confounds. In this 35 prospective neuroimaging-based RCT performed in chronic back pain patients, we demonstrate 36 that the intensity, but not quality, of pain is diminished with placebo pill ingestion. The response 37 to placebo pills depended on brain: subcortical limbic volume asymmetry, sensorimotor cortical 38 thickness, and functional coupling of the dorsolateral prefrontal cortex (DLPFC) with the 39 periaqueductal grey (PAG), the rostral anterior cingulate cortex (rACC), and the precentral gyrus 40 (PreCG); and psychological factors. All features were present before exposure to the pill; most 41 remained stable across treatment and washout periods, although specific functional coupling 42 between DLPFC and PAG dissipated with repeated exposure. These brain properties and specific 43 psychological factors, such as interoceptive awareness and openness, were also predictive of the 44 magnitude of response (continuous variable). We used machine learning in a fully cross-45 validated procedure and demonstrated that psychological factors were sufficient for classifying 46 and predicting response magnitude; and response magnitude could also be predicted from a 47
functional network (nodes mainly located in the limbic community, the DLPFC, the orbitofrontal 48 cortex, and the temporo-parietal junction); the combined model explained 36% of the variance. 49
Together, our results demonstrate that placebo pill analgesia observed in clinical trials depends 50 on a combination of brain properties and specific psychological factors. 51
The placebo effect refers to an improvement in symptoms caused by receiving an inert 52 treatment. The phenomenon has been observed across different conditions, biological systems, 53 and treatment types 1 . Placebo analgesia is especially relevant in the management of chronic 54 pain, since most pharmacological treatments have long-term adverse effects or addictive 55 properties 2 , or show only modest improvements that are insufficient to achieve clinically 56 meaningful amelioration of disability 3 . Moreover, the placebo effect is observed universally in 57 almost all randomized placebo-controlled clinical trials (RCT), particularly in pain treatment 58 trials 4 . The effect size of placebo response is usually equivalent or superior to the active 59 treatment studied and seems to be further increasing in recent RCTs 5 , implying that it will 60 remain a confounding nuisance as long as its underlying properties remain unknown. Yet, 61 current scientific dogma assumes that RCT-related placebo responses are due primarily to 62 uncontrollable confounds 6 . Here, we challenge this assumption by hypothesizing that biological 63 and psychological characteristics predispose chronic pain patients to respond to placebo pills in 64 the settings of a RCT. 65
66
The neurobiological mechanisms underlying the placebo effect have been almost 67 exclusively studied for acute responses to conditioning-type manipulations in healthy 68 individuals, usually performed in the laboratory setting 4 . In healthy subjects, placebo response 69 and its neural and psychological correlates lack consistency across different routes of 70 administration 7-9 . In clinical chronic pain settings, the translation of such findings is 71 questionable not only because chronic pain patients exhibit distinct brain anatomy and 72 physiology 10-13 but also because such patients are repeatedly exposed to a myriad of medical 73 rituals which may bias expectations toward treatment. In fact, two recent neuroimaging studies 74 suggest predictability of the RCT placebo effect based on brain functional properties in different 75 placebo procedures (patch and pill) examined in chronic back pain (CBP) and knee osteoarthritis 76 (OA) conditions [14] [15] [16] . Since functional connectivity is malleable and reflects learned associations 77 17 , and given the hypothesis that the RCT placebo effect is embedded in predictable psychology 78 and neurobiology, we designed and conducted a comprehensive RCT for placebo pill ingestion 79 (in contrast to no-treatment) in CBP patients. 80 81 This prospective cohort study included four neuroimaging sessions and a proper no 82 treatment arm, allowing us to disentangle placebo pill-related analgesia from non-specific 83 effects. We studied two different components of the placebo response based on daily ratings 84 provided by smart phone technology: the presence/absence of response to treatment (Responders 85 (Resp) versus Non-Responders (NonR)), and the magnitude of the response (% analgesia). 86
Prospective questionnaire and neuroimaging data uncovered a multiplicity of parameters 87 underlying placebo pill analgesia: emotion awareness and openness from questionnaires, limbic 88 volume asymmetry and cortical thickness in the precentral gyrus, and functional coupling of the 89 dorsolateral prefrontal cortex (DLPFC) with the periaqueductal grey (PAG), the rostral anterior 90 cingulate cortex (rACC), and the precentral gyrus (PreCG) from resting state functional magnetic 91 resonance imaging (rsfMRI). We used machine learning models on the prospective questionnaire 92 data and neuroimaging data to classify patients into Resp and NonR and to predict their 93 magnitude of response. Our results demonstrate that chronic pain patients exhibit identifiable 94 neurobiological and psychological machinery for placebo pill response in the RCT setting. 95 96 97 On average, responders (PTxResp and NoTxResp) showed a diminution in back pain 120 intensity that stabilized to a constant value of about 20% analgesia for both treatment and 121 washout periods (T1, T2, and W1, W2; fig. 1c ). The magnitude of %analgesia showed a similar 122 pattern for each treatment period ( fig. 1d) . Importantly, phone app pain ratings at the start of 123 treatment (2 ratings on day 1 of T1) already differentiated placebo treatment responders from the 124 other groups ( fig. 1h; fig S3) , indicating that observed analgesia is temporally coupled to placebo 125 pill ingestion only in PTxResp. 126 127 Given the phone app pain stratification, placebo responders showed consistent 20-30% 128 analgesia in two additional measures of back pain intensity: a numerical verbal recall of their 129 average pain experienced over the last week (pain memory; fig. 1f ), and a numeric rating scale at 130 time of visit (NRS, commonly used to quantify pain in clinical trials 18 ; fig. 1g ). Qualitative 131 properties of back pain were also tracked at each visit by two questionnaires: McGill Pain 132 Questionnaire (MPQ) sensory and affective scales and PainDetect. These measures did not 133 differentiate between treatment cohorts, and groupings defined by the pain app permutation test 134 showed an overall time effect, as shown in the example of the MPQ-sensory score ( fig. 1h-i) . We 135 conclude that the RCT placebo response is composed of two components: 1) a pill ingestion-136 related response specifically impacting perceived intensity of chronic pain (table S3), and 2) a 137 non-specific response reflecting the effect of time or the mere exposure to health care (visits) that 138 modulates qualitative pain measures ( fig. 1i ). For the rest of the study, we concentrate on 139 unraveling the mechanisms of the placebo-induced decrease in back pain intensity, using the 140 phone app data. 141
142

Blinding of the analyses 143
In this study, all brain imaging and questionnaires data were analyzed blindly. We employed cell 144 scrambling to generate two random labeling of patients and all group comparisons were 145 performed three times (two times for scramble codes and one time for real labeling). After 146 completing all the analyses, the real labeling was revealed during a public lab meeting. The 147 results are reported only when the real labeling of patients could be properly identified based on 148 the statistical tests. 149 150
Both stable and transient properties of the DLPFC predispose individuals to placebo pill 151 response 152
We examined brain networks constructed from rsfMRI to directly identify functional 153 connectivity that predisposes patients' response prior to placebo pill treatment ( fig. S4 ). Building 154 on previous findings, we derived placebo-related networks of interest from results in OA patients 155 exposed to placebo treatment in an RCT ( fig. 2a) 16 . We performed a modularity analysis 156 segregating the functional networks into 6 communities, and restricted all analyses to the default 157 mode network (DMN), sensorimotor (SM), and frontoparietal (FP) communities, due to their 158 overlap with placebo-related networks observed in OA. Subcortical limbic regions were added 159 along with the PAG because of their involvement for placebo response and in pain chronification 160 ( fig. S4c) . No other exploratory analyses were performed outside of this initially planned 161 strategy. 162 163 A permutation test was performed on the weighted 7,381 resting state connections 164 between all possible pairs of nodes within the modules of interest (FDR-corrected p < 0.05). The 165 edges differentiating the two PTx response groups were all connected to nodes located in the 166 DLPFC (Broadman area 46). Precisely, PTxResp displayed stronger connections for the link 167 DLPFC-preCG, and weaker connections for links DLPFC-rACC and DLPFC-PAG ( fig. 2b, c) . 168
As expected, all three networks differentiated PTxResp from PTxNonR at visit 2 ( fig. 2d-f) . 169
Moreover, the DLPFC-preCG ( fig. 2d ) and the DLPFC-rACC connectivity ( fig. 2e ) showed 170 neither a main effect of time nor an interaction effect of group*time, indicating that these 171 connections represented time-invariant mechanisms that differentiate PTxResp from PTxNonR 172 across all visits. On the other hand, the initial differences between groups of DLPFC-PAG 173 connections dissipated by visit 4 ( fig. 2f) . These results therefore demonstrate the existence of a 174 DLPFC-functional network, whose components either stably or transiently determine the 175 likelihood of placebo pill response. Importantly, each component of this DLPFC-functional 176 network also tracked the magnitude of placebo response ( fig. 2g ). Performing this analysis using 177 scramble codes for labeling patients generated no significant group differences. 178
179
Limbic asymmetry and cortical thickness in the precentral gyrus predispose individuals to 180 placebo pill response 181
The volumes of the NAc, amygdala, and hippocampus were first examined because they 182 represent risk factors for developing pathological emotional states 19,20 and chronic pain 21 . 183 Comparing subcortical volumes between PTxResp and PTxNonR was not informative. Inter-184 hemispheric laterality of the combined volume of these three structures, however, indicated that 185 PTxResp showed rightward limbic volume asymmetry compared to PTxNonR, and this 186 asymmetry was observed in all four visits/scans ( fig. 3a) . Importantly, this result was validated 187 using another brain segmentation software (Freesurfer, fig. S5 ). The differences in anatomical 188 properties of the cortex were assessed with grey matter density and cortical thickness ( fig. S6) . 189
Whole-brain cortical thickness measurements showed that PTxNonR had thicker cortex in the 190 right superior frontal gyrus than PTxResp (fig. 3b ). The identification of brain morphological 191 features, present before treatment and persisting throughout the study, provides evidence for 192 placebo propensity stemming, in part, from stable brain biology. Here again, the scramble codes 193 yielded no significant group differences. 194
195
Interoceptive awareness and openness predispose individuals to placebo pill response 196
Next, we sought to identify psychological parameters predisposing CBP patients to the placebo 197 pill response from a battery of 15 questionnaires with 38 subscales (table S4) collected at visit 1. 198 
Classifying placebo pill response (PTxResp and PTxNonR) using machine learning 207
We used machine learning to determine if placebo response could be predicted from prospective 208 brain imaging and questionnaires data. We used a nested leave-one-out cross validation 209 (LOOCV) procedure where placebo outcome of each patient was predicted using an independent 210 training sample. Within each n-1 patients training sample set, the model parameters were tuned 211 using 10-fold cross-validation. The optimized model showing the least error was then applied to 212 the left-out patient, repeated for every patient. 213
214
We initially used data from the questionnaires to classify the patients into response 215 groups (binary variable approach). Within each training sample set, the scores of the normalized 216 38 subscales were used to build the support vector machine (SVM) classifier. SVM classification 217 achieved an accuracy of 0.72 in classifying placebo pill response [95% CI, 0.56 to 0.85]. 218 Sensitivity of this approach was 0.73 (95% CI, 0.52 to 0.88), and specificity was 0.71 (95% CI, 219 0.44 to 0.90) ( fig. 5a-d ). This level of accuracy was higher than chance determined by a null 220 distribution from 100 scramble labels (0.72 accuracy corresponded to a z-score of 2.68) ( fig. 5b) . 221
222
We next trained a classifier using brain imaging data entering either brain anatomy or 223 rsfMRI as predictors, but they failed at classifying PTxResp and PTxNonR above chance level 224 (accuracies were < than 0.67, which corresponded to a z-score of 1.96). Moreover, adding 225 features from rsfMRI or brain anatomy to the questionnaire data did not improve the classifier's 226 accuracy (accuracy of 0.65). Feature selections and data reduction procedures used in the 227 training sample set are described in the methods. 228
229
Predicting an individuals' placebo pill magnitude of response using machine learning 230
We next used Least Absolute Shrinkage and Selection Operator (LASSO) regression to predict 231 the magnitude of placebo response (continuous variable approach), using a nested LOOCV 232 procedure. The model was trained in n-1 patients in an inner loop using 10 folds cross-233 validations for tuning the LASSO parameters, and then tested in the unseen held out patient, 234 repeated for every patient. 235
236
As with the previous approach, we initially predicted the magnitude of response using 237 just the combination of questionnaire data ( fig. 5e-f fig. 5g) . The model was no longer 242 able to predict the magnitude of response after removing these psychological parameters. This 243 not only indicates their importance for response, but also reveals that neither the traditional 244 personality measures reported in healthy controls under placebo conditioning (e.g., neuroticism, 245 extraversion, optimism) nor any of the chronic pain related personality traits usually linked to 246 severity of symptoms (e.g., anxiety, catastrophizing, and fear of pain) contributed to the 247 prediction. 248 249 Next, we sought to determine if rsfMRI collected prior to placebo pill ingestion could 250 predict the magnitude of response. Within each n-1 patients training sample set, we performed 251 feature selection to identify links correlating with the magnitude of response (robust regression, p 252 < 0.001) prior to the LASSO regression. These connections were used to train a predictive model 253 using 10-fold cross-validation for tuning the LASSO parameters. The model was then tested in 254 the left-out patient, and repeated for every patient ( fig. 5h-i) . Because the number of features and 255 weights differed between each loop, a "consensus" was generated by averaging the weights 256 across the n=43 loops to create a final single set of weights ( fig. 5j ). The resultant network 257 consisted of a combination of 19 weighted connections predicting the magnitude of placebo 258 analgesia. These included links connecting nodes located in bilateral amygdala, the posterior 259 hippocampus, the PAG, the temporo-parietal junction (TPJ), the DLPFC, and the orbitofrontal 260 cortex (OFC) ( fig. 5j) . Linear regression entering the predicted magnitude of response from 261 rsfMRI and from the questionnaires data revealed that both models explained independent 262 variance of the actual response, suggesting that they are complementary one to another ( fig. 5k) . 263 264 Although this set of edges was predictive of magnitude of response prior to the first 265 placebo treatment, the prediction did not generalize to rsfMRI data collected at other visits post 266 treatment. This is likely due to the small number of connections included in our model, which are 267 either changing in time as a consequence of learning and adjustment of expectations with the 268 introduction of a placebo treatment or due to inherent variability of the measurements 269 themselves. 270
271
Finally, applying LASSO regression on features from brain anatomy generated a 272 predictive model, which did not correlate with the actual magnitude of response. The model was 273 therefore not considered significant and is not reported. 274
275
Discussion 276
This is the first brain imaging RCT specifically designed to study chronic pain patients receiving 277 placebo pills compared to a no treatment arm. Daily ratings provided by smart phone technology 278 revealed that patients receiving placebo pills showed stronger pain reduction and a higher 279 response rate compared to patients from the no treatment arm, indicating that placebo pills 280 successfully induced analgesia that could not be explained by the natural history of exposure to 281 the study. Our results show a multiplicity of biological systems, partially overlapping with 282 complex inter-relationships, underlying placebo pill response. The identified systems seem to 283 encompass brain properties known to be involved in chronic pain maintenance or in the 284 transition to chronic pain (e.g., SM cortex thickness/volume 22 ), mechanisms described for 285 placebo response in healthy subjects experiencing acute pain 23 (e.g., involvement of OFC, 286 DLPFC, rACC, and PAG 24,25 ), as well as novel systems we uniquely associate with placebo pill 287 response (e.g., subcortical volume asymmetry, emotional awareness, and functional coupling of 288 the amygdala, hippocampus, TPJ, and PreCG). Models of machine learning applied to 289 prospective questionnaire and brain imaging data were could, only in part, classify placebo 290 response and predict the individuals' magnitude of placebo response. Given the large effect size 291 of RCT placebo responses (also observed here), our results imply that gaining a better 292 understanding of placebo pill response has important clinical utility. Our results demonstrate the 293 psychological, functional, and anatomical determinants of the placebo response and suggest that 294 once patients begin a placebo treatment, their individual pain relief may be predicted in the 295 context of a RCT. 296 297
Placebo pill response and the multifaceted nature of chronic pain 298
One of the main behavioral findings was that the treatment outcomes exhibited a high level of 299 dimensionality that has not been specifically investigated or accounted for in other clinical or 300 basic science studies regarding modulation/perception of pain. We show that placebo treatment 301 impacted a particular dimension of chronic pain (pain intensity) without changing the trajectory 302 of pain quality (which improved in time regardless of placebo treatment). Even among measures 303 of pain intensities, daily ratings, memory, and NRS provided slightly different levels of 304 information about the extent of analgesia and pain fluctuations (NRS did not capture group 305 differences at Tx1). This highlights the importance of examining a multiplicity of pain-related 306 outcomes as the analgesic properties of any given treatment may not be constrained to a single 307 dimension of the pain experience. Most current RCTs assessing new treatments are designed 308 with a single primary outcome representing a "gold standard", thus likely missing on the 309 complexity of treatment effects that chronic pain may exhibit. Our behavioral results stress the 310 importance of moving away from a single, cross-sectional, pain measurement, and demonstrate 311 that distinct dimensions respond differentially to placebo pill ingestion, impacting mainly 312 perceived magnitude and its memory but not its qualities. 313 314
Brain mechanisms of placebo pill response in chronic pain 315
In healthy individuals, the placebo response recruits endogenous pain pathways acting upon the 316 opioid system to regulate descending inhibition from the rACC 26 through the PAG 27 , a 317 mechanism that can be reversed by naloxone 28 . Besides these anti-nociceptive circuits, the 318 placebo effect is also dependent on subcortical circuitry involved in reward/aversion prediction 319 error, as well as higher-order frontal mechanisms (including the DLPFC and the OFC) involved 320 in context generation, expectation of treatment outcomes, and emotional appraisal of events 24 . 321
As such, levels of activation in the DLPFC and the OFC are believed to represent the strongest 322 predictors of experimental placebo response in healthy controls 29 . The present results indicate 323 that these systems are also part of the placebo pill response in CBP patients, although direct 324 correspondences between functional networks and regional activity remain uncertain. The 325 coupling of the DLPFC and rACC with anti-nociceptive circuitry is also consistent with our 326 previous observation that these regions were predictive of placebo response in OA patients 16 . 327 Therefore, there are close correspondences in the mechanisms underlying placebo pill response 328 across different types of pain (chronic back pain, chronic knee pain, and acute experimental pain) 329 and in different settings (RCT vs. laboratory). 330
331
For the placebo response-related network differentiating PTxResp from PTxNonR, the 332 DLPFC-PreCG and DLPFC-rACC links persisted in time and across visits. However, the initial 333 DLPFC-PAG connections differentiating PTxResp and PTxNonR dissipated, likely due to this 334 network being more dependent on learned expectations and thus requiring novel reinforcing 335 experiences to become reactivated. As the DLPFC-PAG includes commonly described brain 336 regions associated with placebo response in healthy subjects, its dissipation with exposure is 337 consistent with evidence pointing to the failure of placebo re-exposure in healthy subjects in 338 replicating the original placebo response 7 . Brain networks predicting the magnitude of response 339 in a fully cross-validated procedure further reveal the contribution of limbic circuitry, TPJ and 340 prefrontal connectivity (DLPFC-PAG and OFC-PreCG) for placebo pill response. Because the 341 model was not stable in the post-treatment visits, its capacity for predicting magnitude of 342 response in a new set of chronic pain patients remains to be determined in further studies. The 343 procedure was nevertheless informative regarding the neurophysiological contributors to the 344 placebo response. Our original experimental design included two washout periods (W1, W2) 345 specifically designed to monitor perturbations in functional features, like DLPFC-PAG, and to 346 observe whether following washout, they would continue to track placebo pill responders. 347
Unfortunately, the pain trajectories showed sustained effects of placebo analgesia during 348 washout periods that were proven too short to be informative. 349 awareness, decreased worrying about discomfort, augmented capabilities in describing inner 357 experiences, and higher sensitivity to non-painful situations. Our results reveal that placebo 358 response can be predicted from an ability to recognize subtle cues in the body regarding 359 emotional and physical well-being, to remain attentive to these cues and emotions by not 360 ignoring or suppressing them, and to choose to accept these states as opposed to becoming 361 worried or burdened by them. These factors of personality were able to differentiate PTxResp 362 and PTxNonR as well as predict the magnitude of placebo response in new patients. These 363 results are critical, as questionnaires are easy to administer and may be sufficient to predict 364 placebo pill response without the need of expensive brain imaging data. 365 366
Conclusions 367
Several pitfalls have been raised when trying to predict complex behaviors like the placebo 368 response 34 . Here, many of these potential confounds were accounted for by incorporating novel 369 methodological strategies such as: including a no-treatment arm documenting the natural history 370 of the patients, using smart phone technology accounting for natural fluctuations of pain outside 371 of the clinical setting, collecting multiple pain outcome measures, performing analyses blindly 372 using one real code and two scrambled codes to minimize bias, and utilizing unbiased machine 373 learning methods to estimate predictability in a fully cross validated procedure. 374 375 Some have argued that clinical trials do not provide an appropriate context to study the 376 psychobiology of placebo because it is contaminated by uncontrollable confounds and that 377 placebo should be studied in a controlled environment such as the settings of a laboratory 6 . 378
Despite the complexity of the phenomenon, our results challenge this assumption as placebo 379 response could be predicted in chronic pain patients. Actually, our results raise the possibility 380 that placebo response may be more predictable in people experiencing spontaneous pain in the 381 context of a clinical trial, precisely because expectations toward treatment are different in 382 patients that would truly benefit from chronic pain relief. At minimum, our results indicate that 383 placebo effect rituals, as used in some form or fashion for millennia, have their own 384 psychological and neurobiological determinants. 
390
The total duration of the study lasted approximately 15 months. The first patient was seen on 11/06/14, 391 and the last patient was seen on 02/04/16. During that time, 129 participants with chronic low back pain 392 (CBP) were initially recruited from the general population and clinical referrals via hospital databases and 393 advertising in the community. To meet inclusion criteria, individuals had to be 18 years or older with a 394 history of lower back pain for at least 6 months. This pain should have been neuropathic (radiculopathy 395 confirmed by physical examination was required), with no evidence of additional co-morbid chronic pain, 396 neurological, or psychiatric conditions. Individuals had to agree to stop any concomitant pain medications 397 and had to be able to use a smartphone or computer to monitor pain twice a day. Additionally, the 398 enrolled patients had to report a pain level of at least 5/10 during the screening interview, and their 399 averaged pain level from the smartphone app needed to be higher than 4/10 during the baseline rating 400 period (explained below) before they were randomized into a treatment group. Finally, for safety 401 precautions, clinical measurements taken at Visit 1 were required to be within the pre-specified healthy 402 range and all participants passed the MRI safety screening requirements at each scanning visit. were stored at room temperature in a locked cabinet within the lab. The double blind for treatment groups 439 was maintained by the identical encapsulation of the study agent -blue pills were either Naproxen 440 (500mg) or placebo (lactose) and bi-colored pills were either Esomeprazole (20mg) or placebo. Each 441 person assigned to treatment received a mixture of blue and bi-colored pills. This way, neither the 442 participants nor the researchers knew which treatment the participant had received. For those assigned to 443 the no-treatment group, no blind was maintained, as both study staff and participants knew that they were 444 not receiving the study agent. Once approximately 50% of all participants had been entered into the study, 445 a preliminary analysis of the electronic pain rating data was completed in order to confirm that there were 446 participants who were experiencing a diminution in pain (no action was taken). ; fig. S2 ); if participants did not have access to either, they were provided with a 469 smartphone and data plan for the duration of the study. The baseline rating period started at the end of this 470 visit and lasted until they came back for their second visit approximately two weeks later.
404
448
Description of visits
472
Visit 2 473 If patients' pain ratings and blood lab results met inclusion criteria, they returned for Visit 2 where they 474 completed a 35-minute brain imaging session that collected a T1-weighted image, 2 resting state scans, 475 and 2 diffusion tensor imaging (DTI) scans (details are presented below). Following the imaging protocol, 476 the patients completed another battery of questionnaires, a subset of which were repeated from the first 477 visit to track longitudinal changes in pain. They were asked whether they had experienced any changes in 478 health status since the last visit. Additionally, they were asked to verbally recall their average pain levels 479 over the previous 2 weeks, and over the preceding week. This self-reported recalled pain was referred to 480 as "pain memory" and was used as an alternative outcome measure of pain levels.
482
At the end of this visit, participants were randomized into one of three groups: no-treatment, 483 placebo treatment (lactose) or active treatment (the standard of care, which was a combination of 484 Naproxen, 500 mg bid, and Esomeprazole, 20 mg bid). Participants in the treatment groups were 485 instructed to take a blue pill with a bi-colored pill in the morning and again at night with plenty of water, 486 and they were asked to record this in their electronic rating app. Note that study staff never informed 487 participants about the odds for receiving active versus placebo treatment -this is important, as the goal 488 was to have participant's own baseline expectations influence whether or not they responded to the 489 placebo treatment. Both treatment and no treatment groups continued to receive rescue medication to use 490 if needed, and all participants were asked to continue rating their pain twice a day until Visit 3. The 491 duration of this first treatment period was ~2 weeks long.
493
Visit 3 494 Patients returned at Visit 3 and were queried about their memory of their pain, any changes in health since 495 the last visit, and rescue medication usage. If on treatment, patients were asked to report any side effects 496 experienced and bring back any unused medication so that study staff could calculate their treatment 497 compliance. Participants underwent another scanning session that was identical to the one completed at 498 Visit 2 and completed another set of questionnaires with some repeated from the previous visit. At the end 499 of Visit 3, individuals assigned to the treatment group were told that the study agent would be temporarily 500 discontinued until their next visit so that the effects of the agent could "wash out" of their system. Again, 501 all participants were given rescue medication to use if needed and were asked to continue using their app 502 twice a day until the next visit. This first washout period was ~1 week long.
504
Visit 4 505 Patients returned at Visit 4, where all measurements and procedures from Visit 2 were repeated 506 identically, including the scanning session and questionnaires. Again, they were queried about their pain 507 memory, rescue medication usage, and changes in health. The study agent was reintroduced to those 508 individuals allocated to one of the treatment groups according to the same regimen described above 509 (treatment assignment was kept the same within subjects, as this was not a cross-over study design).
510
Patients were informed that they were receiving the same treatment than the one administered during the 511 first treatment period. All participants were given rescue medication and asked to rate their pain and 512 mood twice a day, as with previous visits. Like the first treatment period, the second treatment period was 513 also ~2 weeks in length.
515
Visit 5 516 Following this period, participants returned for Visit 5, where all measurements and procedures from 517 Visit 3 were repeated identically. Patients underwent the same scanning procedures as on visits 2-4.
518
Finally, patients filled out a series of questionnaires about their pain, some of which were repeated from 519 the last visits. As before, those participants allocated to a study agent had their treatment discontinued for 520 a second washout period, which was also approximately 1-week long. Participants continued to use their 521 electronic app twice daily and were given rescue medication if needed. 
523
533
Monitoring pain intensity with phone app 534 Each patient's pain was monitored electronically using an application designed specifically for the study 535 ( fig. 1; fig S2) . This app was used to track patients' pain over time and to query them on their medication 536 usage; it could be accessed using either a smartphone or a website link on a computer. The app had a 537 VAS scale with sliding bars: it asked participants to rate their current pain level from 0 (no pain) to 10 538 (worst imaginable). The app also included fields to indicate the participant's assigned ID number, query if 539 participants had taken any rescue medication at that time, and ask if they had taken the study medication.
540
There was a comments section that they could use to describe their pain, mood, or medication usage if 541 they chose. Participants were instructed to use the app twice a day, once in the morning and once at night.
542
To encourage compliance, participants were compensated $0.25 for each rating they submitted, up to 543 $0.50/day. This additional payment was given to them on the last visit of the trial. Submitted ratings were 544 immediately sent to a secure server and both date-and time-stamped. Rating compliance was assessed by 545 a separate program, which monitored whether the list of currently enrolled patients had provided the 546 necessary ratings during the previous day. In the case that a patient omitted a rating, staff were alerted via 547 an email. If patients missed more than 2 consecutive ratings (~24 hours-worth), a member of the study 548 team contacted them to remind them to use the app. Two patients were discontinued from the study 549 because they did not comply with the daily rating requirements despite repeated contact from the study 550 team.
552
To verify that pain levels remained within the inclusion criteria specified above, all participants' 553 ratings were closely monitored for the first two weeks of the study as part of a run-in/baseline pain period.
554
Individuals not meeting this level were deemed ineligible and did not continue in the study (n=16 screen 555 failures). It was later noticed that 3 additional participants had met this exclusion criteria but accidentally 556 continued in the study. One person was assigned to no-treatment and was discontinued as a protocol 557 deviation before study completion; the other two individuals finished the study in the placebo treatment 558 group but were not included in the analysis.
560
Preprocessing of phone app ratings and defining placebo response 561 App rating data from all participants were pre-processed as follows. Although participants were asked to 562 rate twice a day (and only compensated for this amount), many participants exceeded this number of app 563 ratings in 24 hours due to over-compliance, reassessment of their pain, and/or cellular service problems. If 564 pain ratings were entered within 30 minutes of each other, only the last rating was kept and taken as 565 indicative of the participant's final assessment of their pain levels at that time. Any additional ratings 566 outside of this 30 minutes window were not considered duplicates and were kept as valid entries. Beside 567 this cleaning process, no other changes were made to the ratings. In the instances where participants 568 missed ratings, no attempts were made to interpolate or re-sample the data so that the temporal aspects of 569 the ratings were left intact. The overall compliance of the phone ratings is reported for each group in 570 table S2.
572
Defining placebo response 573 This smartphone technology permitted us to track fluctuation in pain levels throughout the study . Fig 1b   574 displays the time series generated using the pain ratings entered by participants PL001 and PL039. In this 575 study, we assessed two different components of the placebo response: the response or absence of response 576 as well as the magnitude of the response. To best make use of the daily rating data, we initially developed 577 a new classification scheme of responders versus non-responders that accounts for the within-subject 578 variability of pain levels. Each patient was classified based on a permutation test between the pain ratings 579 acquired during his baseline rating period (Visit 1 to Visit 2) and the pain ratings acquired during his 580 treatment periods (either baseline versus treatment 1, or baseline versus treatment 2). The null hypothesis 581 was generated by randomly resampling 10,000 times the distribution of pain ratings, which provides a 582 large set of possible t-values obtained from the rearrangement of the pain ratings. The overall t-value 583 obtained between baseline and treatment was used to determine if the null hypothesis could be rejected 584 (p<0.05) for each of the treatment periods. In the cases where the null hypothesis could not be rejected for 585 either of the treatment periods, the patient would be stratified as a "Non-Responder". Alternatively, the 586 patient would be stratified as a "Responder" if there was a significant diminution in the pain ratings. The 587 main advantages of using a permutation test is that it takes into consideration the variability across pain 588 ratings during the baseline and treatment periods and it represents a statistically-defined cut-off point for 589 response (unlike cut-off points arbitrarily defined by a percentage change in pain).
591
Because group stratification may have dampened individual response to placebo treatment, we 592 secondly studied the magnitude of response by subtracting the averaged pain ratings entered during the 593 baseline period with the averaged pain ratings entered during the last week of each treatment period 594 separately. The magnitude of analgesia was defined as the highest difference between baseline and the 2 595 treatment periods. This provides a different facet of placebo response: the placebo response identifies 596 significant improvement of symptoms (a small but constant improvement of symptoms may have 597 stratified a patient as a placebo responder) while the % analgesia rather represents a continuous measure 598 determining the importance of the response. 
615
Blinding of the analysis 616 Given the recent issues regarding a lack of reproducibility in scientific findings 37 , and the importance of 617 transparency in data analysis, we followed recommendations by MacCoun and Pearlmutter 38 and 618 employed cell scrambling to further blind our data and minimize bias. For all endpoints, a lab member not 619 involved in analyses was selected to organize data files and spreadsheets for processing and statistical 620 analyses of the data. This person first renamed all the data files in order to ensure that analysts were 621 blinded to each participant's unique ID, and to minimize bias from previous interactions with patients 622 during data collection. Next, all analyses were performed with 3 randomized codes (which we refer to 623 here as "classifiers") for each condition, with only one of them being the proper classification of placebo 624 treatment responders, non-responders, and no treatment responders and non-responders. We refer to this 625 as "triple blinding" because analyzers were blind to participant ID, participant treatment, and correct 626 participant group classification. The selected lab member did this blinding prior to any analyses, with the 627 exception of the pain ratings from the app, which were used to stratify patients from the outset. As a 628 result, each analysis was done three different times in an unbiased manner. Importantly, the three lab 629 members who contributed to the analyses were not informed that they were provided different classifiers 630 to make sure they could not collaborate to figure out which one was the real code. The results were 631 presented in a public lab meeting where the lab member un-blinded the analyzers to the data to confirm 632 which results were true. Although we refer to these 3 classifiers throughout the paper, we only present the 633 outcomes and data from the correctly classified group in each instance. Results from the 2 false classifiers 634 are presented where applicable in supplementary material for the purpose of comparison. This procedure 635 aims to decrease uncontrolled bias during data analyses and to enhance the reproducibility of results.
637
Brain imaging Protocol and Data Analysis
638
The entire procedure was completed in about 35 minutes, but an extra 25 minutes was allocated to install 639 the patients in a comfortable position to keep their back pain at a minimum, and to re-acquire images if 640 the data was contaminated by head motion.
641
Community detection analyses 693 We used the Louvain algorithm integrated in the Brain Connectivity Toolbox (BCT; 694 https://sites.google.com/a/brain-connectivity-toolbox.net/bct/ 40 ) to determine consistent community 695 structures across a large number of network partitions 41 . For each subject, the individual community 696 structure was initially constructed from 100 repetitions of the same network. The group community was 697 then constructed from 100 x 63 patients, generating a total of 6300 networks. The final community 698 structure was created by thresholding the averaged within-module connectivity likelihood matrix at 0.5, 699 meaning that if the likelihood for two nodes belonging to the same module was above 50%, they were 700 considered in the same module. This permitted us to identify six separate communities, including the four 701 communities of interest ( fig. 2a ).
703
Identifying communities of interest 704 We used localizers from an independent data set consisting of osteoarthritis patients where placebo 705 response was predicted from resting state fMRI functional connectivity 16 . We used resting state 706 functional connectivity to identify four regions predicting patients in the placebo arm that responded to 707 treatment: the right mid-frontal gyrus connectivity (x=28, y=52, z=9), the anterior cingulate cortex (x=-3, 708 y=40, z=2), the posterior cingulate cortex (x=-1, y=-45, z=15) , and the right somatosensory cortex (x=60, 709 y=-7, z=21). We next entered these coordinates as seeds in the Neurosynth analytic tool 710 (http://neurosynth.org) and extracted three networks sharing strong connectivity with these seeds: the 711 DMN, the frontoparietal network, and the sensorimotor network. We identified communities 712 corresponding to these networks based on spatial overlap, by multiplying the networks of interest with the 713 nodes pertaining to each community. A total of 113 nodes were affiliated with these communities (fig2. 714 a). The 151 nodes affiliated with the visual and saliency communities and those nodes without affiliation 715 to any community were excluded from the analyses. The limbic nodes and a node located in the PAG 716 from the Power parcellation scheme (which was not affiliated with any community) were added for a total 717 of 122 nodes of interest. This approach was part of our initial analysis design because it has many 718 advantages, including increasing statistical power by limiting the number of comparisons, preventing 719 over-fitting of the data, and identifying hypothesis-driven functional networks with the potential of 720 generalizing obtained results across different chronic pain conditions.
722
Network statistics 723 Network statistics were performed to identify brain networks predisposing to placebo response 724 (performed on the 122x122 connectivity matrix). Group differences were examined using a permutation 725 test (5,000 permutations) on the connections of the weighted network (122 * 121 nodes), controlling for 726 false discovery rate (FDR p < 0.05) using the Network Based Statistics toolbox (NBS; 42 ). The fisher-z 727 transformed correlation coefficients z(r) of the significant connections were extracted at each visit and 728 entered in a repeated measured ANOVA testing for an interaction of time with placebo treatment 729 response.
731
Voxel based morphometry 732 Grey matter density was examined using voxel-based morphometry from FSLVBM. All T1-weighted 733 images were first brain extracted and then segmented into grey matter, white matter, or cerebrospinal 734 fluid. A common grey matter template was generated for CBP by registering and averaging all grey 735 matter images. The grey matter image of each participant was then registered to the common template 736 using non-linear transformation. A voxel-wise permutation test was used to test the significance of group 737 differences between placebo responders and non-responders to a distribution generated from 5000 738 permutations of the data for each voxel of the template, using a sigma filter of 3 mm for smoothing. The 739 initial analysis established significance level using the Threshold-Free Cluster Enhancement (TFCE) 740 method (FWE p < 0.05).
742
Cortical thickness 743 Cortical thickness was examined using Freesurfer software library (http://surfer.nmr.mgh.harvard.edu/).
744
In brief, the structural processing includes skull stripping, intensity normalization, Taliarch registration, 745 segmentation of the subcortex, reconstruction of the cortical surface, and tessellation of the gray/white 746 matter boundary and pial surface. Following reconstruction of the cortical surface, brains were inflated, 747 averaged across participants to produce a study-specific brain, and then smoothed using a 10 mm full-748 width at half maximum Gaussian kernel. A direct measure of cortical thickness was calculated using the 749 shortest distance (mm) between the pial surface and gray-white matter boundary at each point or vertex. showing that subcortical volume asymmetry can provide a brain signature for psychopathologies 44 , we 768 also investigated the possibility that asymmetry differences may provide a biomarker for placebo 769 propensity in our data. All subcortical regions' volumes were summed for the right and the left 770 hemisphere separately; for each patient, the ratio between the two (right/left) was created, where a result 771 =1 would be indicative of perfect subcortical symmetry, whereas numbers >1 or <1 would indicate 772 asymmetry biased toward the right or left hemispheres, respectively. Volumes and subcortical asymmetry 773 were compared between PTxNonR, PTxResp, NoTxNonR, NoTxResp using a one way ANCOVA 774 controlling for peripheral peripheral grey matter volume, age and sex. The effect was tested across all 775 visits using repeated measure ANCOVA controlling for peripheral peripheral grey matter volume, age, 776 and sex.
778
Analysis of Questionnaire Data
779
Over the course of the 6 visits, participants filled out 29 unique questionnaires. These specific self-report 780 measures were chosen for one of 4 reasons: (1) to gather basic information about participants, including 781 demographics and pain/medical history, (2) to track any changes in the quality and/or intensity of pain 782 characteristics as measures of treatment efficacy, (3) to monitor any changes in emotional affect which 783 may have influenced someone's time in the study or their treatment response, and (4) to capture trait-784 based qualities, general habits and beliefs, or state-related expectations of individuals that may predispose 785 them to respond to placebo. Questionnaires used to track pain and mood changes overtime were repeated 786 across all study visits. Questionnaires that targeted expectations towards treatment and satisfaction after 787 treatment were conducted twice -either before treatment sessions (visits 2 and 4) or after treatment 788 periods (visits 3 and 5), respectively. In contrast, measures that aimed to identify more stable traits of 789 participants were completed at visit 1, which allowed us to use them as possible predictors of response.
790
Finally, a subset of questionnaires regarding beliefs toward alternative medicines and suggestibility were 791 administered at the final visit after the exit interview. A full list of all questionnaires used, along with 792 descriptions and references, can be found in table S4. The data analyzed here, with the exception of the 793 pain questionnaires collected at every visit to determine treatment outcome, come from those 794 questionnaires collected at visit 1 only, as we were interested in looking at predictors of placebo response.
796
Data from these self-report measures were downloaded directly from REDCap as a CSV file and 797 scored in Excel according to their references. Because all questionnaires were converted to an electronic 798 format in order to be used in REDCap, an option to "skip" a question was provided if the participant did 799 not feel comfortable answering a certain item. If more than 20% of the data from a given questionnaire 800 (or questionnaire subscale, if applicable) was missing, the person's data for the questionnaire was not 801 scored; for all other missing data, the mean was used to fill in missing items (if the questionnaire had sub-802 scoring, the mean was calculated from the remaining items in the sub-dimension as opposed to the entire 803 questionnaire); this approach is one of the most commonly used methods in data analysis 45 . It was 804 utilized in order to conserve statistical power, given our relatively small sample size. Of all the self-report 805 data analyzed, less than 3% was totally missing and thus unable to be filled in as described above.
807
Machine learning analyses 808 The predictive value of brain imaging and questionnaires data was tested using models of machine 809 learning. We implemented a nested leave one out cross validation (LOOCV) procedure where models 810 were trained in an inner loop (n=42) and applied to a left out participant. The purpose of the inner loop 811 was to optimized the parameters of the model through cross validation. Once the optimal model showing 812 the least amount of error was identified, it was applied to the left out participant to either classify the 813 patient as a PTxResp or PTxNonR or predict the magnitude of his response. This procedure was applied 814 to build predictive model from rsfMRI, brain anatomy and personality independently.
816
Features selection 817 rsfMRI: The model was built based on the weighted 7,381 connections from the matrices used for 818 network analyses. Feature selection was initially performed within the inner loop using several data 819 reduction strategies: principal component analyses (PCA; 42 components), unsupervised machine 820 learning (CorEx (https://github.com/gregversteeg/CorEx); 40 variables), or averaged connectivity within 821 and between communities. Features selection was also performed using univariate t-test on each 822 connections to identify group differences (PTxResp Vs PTxNonR within the raining set; p < 0.001) or 823 links correlating with the magnitude of response (robust regression with %anagesia within the raining set; 824 p < 0.001).
825
Anatomy: Three different measures were used to predict the magnitude of response using brain anatomy: 826 1) the averaged cortical thickness in the 74 labels per hemispheres from the Destrieux Atlas 46 , 2) volumes 827 of the 16 subcortical structures segmented with FSL FIRST, 3) subcortical volume asymmetry (ratio 828 Right/Left) of these 16 subcortical structures. Because the features were derived from different 829 measurements, the data was normalized.
830
Questionnaires: All 38 items collected at V1 were entered in the model. Because the questionnaires were 831 on different scales, the data was normalised.
833
SVM for classifying PTxResp and PTxNonR 834 Support vector machine (SVM) was used to discriminate between PTxResp and PTxNonR using fitcsvm 835 function implemented in Matlab. We implemented a nested leave one out cross validation (LOOCV) 836 procedure where SVM models were trained in an inner loop (n=42) and applied to a left out participant.
837
The box constraint and the radial basis function (rbf) kernel were optimized through a 10 folds cross 838 validation strategy within the inner loop. Once the optimal SVM model was identified, it was applied to 839 classify the left-out patient as a PTxResp or PTxNonR.
841
LASSO for predicting magnitude of response 842 We used Least Absolute Shrinkage and Selection Operator (LASSO) regressions to train a model 843 predicting the magnitude of response. Here again, we used a nested LOOCV procedure where models 844 were trained in an inner loop (n=42) and applied to a left-out participant. The inner loop determined 845 feature selection and lambda regularization parameters using 10 folds cross-validation. The generalization 846 error was estimated by testing the model to the left-out patient. The procedure was performed using the 847 lasso function, implemented in Matlab.
848
Statistical analyses 849 A description of each statistical test and its exact values are reported in table S6.
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